MedKoo Cat#: 412560 | Name: Centanafadine
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Centanafadine is a dual norepinephrine-dopamine transporter inhibitor used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Chemical Structure

Centanafadine
CAS#924012-43-1 (free base)

Theoretical Analysis

MedKoo Cat#: 412560

Name: Centanafadine

CAS#: 924012-43-1 (free base)

Chemical Formula: C15H15N

Exact Mass: 209.1204

Molecular Weight: 209.29

Elemental Analysis: C, 86.08; H, 7.22; N, 6.69

Price and Availability

Size Price Availability Quantity
5mg USD 365.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Synonym
Centanafadine free base; EB1020 free base; EB-1020 free base; EB 1020 free base
IUPAC/Chemical Name
3-Azabicyclo(3.1.0)hexane, 1-(2-naphthalenyl)-, (1R,5S)-
InChi Key
HKHCSWPSUSWGLI-CABCVRRESA-N
InChi Code
InChI=1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2/t14-,15+/m1/s1
SMILES Code
[H][C@@]12CNC[C@]1(C3=CC=C4C=CC=CC4=C3)C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 209.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Schoretsanitis G, de Leon J, Eap CB, Kane JM, Paulzen M. Clinically Significant Drug-Drug Interactions with Agents for Attention- Deficit/Hyperactivity Disorder. CNS Drugs. 2019 Dec;33(12):1201-1222. doi: 10.1007/s40263-019-00683-7. PMID: 31776871. 2: Nageye F, Cortese S. Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD. Expert Rev Neurother. 2019 Jul;19(7):707-717. doi: 10.1080/14737175.2019.1628640. Epub 2019 Jun 26. PMID: 31167583. 3: Wigal SB, Wigal T, Hobart M, Madera JJ, Baker RA, Kohegyi E, McKinney A, Wilens TE. Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies. Neuropsychiatr Dis Treat. 2020 Jun 8;16:1411-1426. doi: 10.2147/NDT.S242084. PMID: 32606695; PMCID: PMC7292254.